ArticlePsychopharmacology2010
Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice.
Article in Psychopharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- A meta-analysis of deep brain structural shape and asymmetry abnormalities in 2,833 individuals with schizophrenia compared with 3,929 healthy volunteers via the ENIGMA Consortium.Human brain mapping · 2022Pooled it
- Effects of antipsychotic D2 antagonists on long-term potentiation in animals and implications for human studies.Progress in neuro-psychopharmacology & biological psychiatry · 2014Pooled it
- Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.Biomedicines · 2022Review
- The microbial metabolite p-Cresol induces autistic-like behaviors in mice by remodeling the gut microbiota.Microbiome · 2021Article
- Article
- Article
- Beyond Neuronal Microtubule Stabilization: MAP6 and CRMPS, Two Converging Stories.Frontiers in molecular neuroscience · 2021Article
- Pyr1-Mediated Pharmacological Inhibition of LIM Kinase Restores Synaptic Plasticity and Normal Behavior in a Mouse Model of Schizophrenia.Frontiers in pharmacology · 2021Article
- Defective tubulin detyrosination causes structural brain abnormalities with cognitive deficiency in humans and mice.Human molecular genetics · 2019Article
- Impact of Chronic Risperidone Use on Behavior and Survival of 3xTg-AD Mice Model of Alzheimer's Disease and Mice With Normal Aging.Frontiers in pharmacology · 2019Article
- Deletion of the microtubule-associated protein 6 (MAP6) results in skeletal muscle dysfunction.Skeletal muscle · 2018Article
- A key function for microtubule-associated-protein 6 in activity-dependent stabilisation of actin filaments in dendritic spines.Nature communications · 2018Article
- 3D imaging of the brain morphology and connectivity defects in a model of psychiatric disorders: MAP6-KO mice.Scientific reports · 2017Article
- Potential Role of Microtubule Stabilizing Agents in Neurodevelopmental Disorders.International journal of molecular sciences · 2017Review
- Disruptions of Sleep/Wake Patterns in the Stable Tubule Only Polypeptide (STOP) Null Mouse Model of Schizophrenia.Schizophrenia bulletin · 2016Article
- Microtubule-associated protein 6 mediates neuronal connectivity through Semaphorin 3E-dependent signalling for axonal growth.Nature communications · 2015Article
- Postmortem brain: an underutilized substrate for studying severe mental illness.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Review
- Reduced expression of STOP/MAP6 in mice leads to cognitive deficits.Schizophrenia bulletin · 2013Article
- Structural basis for the association of MAP6 protein with microtubules and its regulation by calmodulin.The Journal of biological chemistry · 2013Article
- Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecent studies have suggested that schizophrenia is associated with alterations in the synaptic connectivity involving cytoskeletal proteins. The microtubule-associated protein stable tubule only polypeptide (STOP) plays a key role in neuronal architecture and synaptic plasticity, and it has been demonstrated that STOP gene deletion in mice leads to a phenotype mimicking aspects of positive and negative symptoms and cognitive deficits classically observed in schizophrenic patients. In STOP null mice, behavioral defects are associated with synaptic plasticity abnormalities including defects in long-term potentiation. In these mice, long-term administration of typical antipsychotics has been shown to partially alleviate behavioral defects but, as in humans, such a treatment was poorly active on deficits related to negative symptoms and cognitive impairments. Here, we assessed the effects of risperidone and clozapine, two atypical antipsychotics, on STOP null mice behavior and synaptic plasticity.
resultsLong-term administration of either drug results in alleviation of behavioral alterations mimicking some negative symptoms and partial amelioration of some cognitive defects in STOP null mice. Interestingly, clozapine treatment also improves synaptic plasticity of the STOP null animals by restoring long-term potentiation in the hippocampus. DISCUSSION: All together, the pharmacological reactivity of STOP null mice to antipsychotics evokes the pharmacological response of humans to such drugs. Totally, our study suggests that STOP null mice may provide a useful preclinical model to evaluate pharmacological properties of antipsychotic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.